GlaxoSmithKline Case Study by cee-cee

A business case study analysis with internal and external environment SWOT (strengths, weaknessses, opportunities, threats) analyses for the pharmaceutical company, GlaxoSmithKline.
# 108744 | 5,223 words | 12 sources | MLA | 2008 | US
Published on Oct 26, 2008 in Business (Companies) , Business (Applied Operations)

$19.95 Buy and instantly download this paper now


This paper provides a business case analysis of GlaxoSmithKline, a renowned pharmaceutical company. It describes the company's current performance and their business objectives. The paper also provides a SWOT (strengths, weaknesses, opportunities, threats) analysis for the internal environment and the external environment of the company. Finally, the paper looks at strategic alternatives and provides recommendations for the future of the company. The paper is largely in point form.

Table of Contents:
Current Situation
Current Performance
Strategic Posture
Corporate Governance
Board of Directors
Top Management
External Environment: Opportunities and Threats (SWOT)
Societal Environment
Task Environment
Summary of External Factors
Internal Environment: Strengths and Weaknesses (SWOT)
Corporate Structure
Corporate Culture
Corporate Resources
Research and Development (R&D)
Operations and Logistics
Human Resource Management
Information Systems (IS)
Summary of Internal Factors
Analysis of Strategic Factors (SWOT)
Situational Analysis
Review of Mission and Objectives
Strategic Alternatives and Recommended Strategy
Strategic Alternatives
Push Strategy
Reduce Production Costs
No Change Strategy
Recommended Strategy
Reduce Production Costs
Evaluation and Control

Sample of Sources Used:

  • 2007, GlaxoSmithKline PLC GSK Ratios, Reuters Information on Stocks,, last accessed on October 26, 2007
  • GlaxoSmithKline Official Website,, last accessed on October 28, 2007
  • GlaxoSmithKline Annual Report for 2006, A Human Race, Retrieved on October 28, 2007 from
  • Smith Shull, S., Morris, R.J., 2003, GlaxoSmithKline's Retaliation Against Cross-Border Sales of Prescription Drugs
  • Boseley, S., February 18, 2003, Jean Pierre Garnier, Head of Glaxo, The Guardian,,,897344,00.html, last accessed on October 26, 2007

Cite this Case Study:

APA Format

GlaxoSmithKline (2008, October 26) Retrieved March 01, 2024, from

MLA Format

"GlaxoSmithKline" 26 October 2008. Web. 01 March. 2024. <>